臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 52893107 在线人数 : 844 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 361-370 / 881 (共89页)
<< < 32 33 34 35 36 37 38 39 40 41 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-03-09T05:18:34Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:33Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:33Z	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression	Hsu C.; Ying-Chun Shen; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Yeh K.-H.
臺大學術典藏	2021-03-09T05:18:32Z	Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer	Ying-Chun Shen; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:32Z	erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5)	Hsu C.; Ying-Chun Shen; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Yeh K.-H.
臺大學術典藏	2021-03-09T05:18:32Z	Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma	Ying-Chun Shen; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:31Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:31Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:30Z	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO	Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Ying-Chun Shen; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y.
臺大學術典藏	2021-03-09T05:18:29Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Ying-Chun Shen; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.

显示项目 361-370 / 881 (共89页)
<< < 32 33 34 35 36 37 38 39 40 41 > >>
每页显示[10|25|50]项目